How do you approach patients with SDH deficient advanced GIST tumor for systemic treatment?

Would you consider using repretinib as first line therapy given its novel mechanism of action versus other treatment options?

Answer from: Medical Oncologist at Academic Institution

For SDHB mutant GIST (the most common SDH mutation), I try to observe them for as long as possible and resect the enlarging lesions when possible (NF1 and SDH mutant GIST tend to grow slowly compared with their KIT/PDGFR mutant counterparts). If no surgical resection options are available, ...

Related Questions